(Q36954152)

English

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri

scientific article published on 16 September 2015

Statements

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri (English)
Cornelia L Trimble
Matthew P Morrow
Kimberly A Kraynyak
Ami Shah Brown
Kathleen Marcozzi-Pierce
Albert J Sylvester
Timothy A Herring
Niranjan Y Sardesai
Mark L Bagarazzi

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit